Oncology Central

The role of PET/CT for nodal staging in primary stage II/III breast cancer patients


Modalities that are conventionally used for regional and distant metastases staging, in clinical stage II/III breast cancer patients (ultrasonography, computed tomography [CT], MRI and bone scan), may underestimate the spread of the disease. The 18-fluoro-deoxy-glucose whole body PET with CT (18F-FDG PET/CT) is able to more accurately visualize the number of axillary lymph node metastases, the internal mammary chain, periclavicular lymph node metastases and distant disease than the previously mentioned modalities.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.